Results 51 to 60 of about 22,135,772 (359)

Sectoral Patterns of Technical Change : Towards a Taxonomy and a Theory : Research Policy

open access: yes, 1984
Previous representations of the processes of technical change found in economics are deficient because they make the production of technology and innovations exogenous and they do not reflect the considerable variety of the sources.
K. Pavitt
semanticscholar   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

BSE: Risk, Uncertainty, and Policy Change [PDF]

open access: yes, 2002
The authors discuss how, in our risk society, a range of potential risks and uncertainties are associated with new technologies and new diseases, such as BSE.
Cummins, Enda   +3 more
core   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

open access: yesMolecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard   +12 more
wiley   +1 more source

Screening for lung cancer: A systematic review of overdiagnosis and its implications

open access: yesMolecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz   +12 more
wiley   +1 more source

Limiting Terms of Office for Directors as a Policy Change in the Israeli Nursing System [PDF]

open access: yesRevista de Management Comparat International, 2018
Background: This study examines the phenomenon of arrangements limiting terms of office for directors of nursing (DONs) as a policy change in the Israeli public healthcare system since nursing is a major component of the healthcare system's personnel ...
Inga SHALEV, Adriana PRODAN
doaj   +1 more source

The diffusion of climate change adaptation policy

open access: yesWIREs Climate Change, 2022
Adapting to some level of climate change has become unavoidable. However, there is surprisingly limited systematic knowledge about whether and how adaptation policies have diffused and could diffuse in the future.
J. Schoenefeld, K. Schulze, Nils Bruch
semanticscholar   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Playing the policy game: a review of the barriers to and enablers of nutrition policy change

open access: yesPublic Health Nutrition, 2016
Objective To progress nutrition policy change and develop more effective advocates, it is useful to consider real-world factors and practical experiences of past advocacy efforts to determine the key barriers to and enablers of nutrition policy change ...
K. Cullerton   +3 more
semanticscholar   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy